Premium
Allogeneic bone marrow transplantation with T‐cell‐depleted marrow grafts for patients with poor‐risk relapsed low‐grade non‐Hodgkin's lymphoma
Author(s) -
Caroline Mandigers,
John Raemaekers,
A.V.M.B. Schattenberg,
Edwin Roovers,
M.J.J.T. Bogman,
Richard W.M. van der Maazen,
B.E. de Pauw,
T.J.M. de Witte
Publication year - 1998
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1998.00539.x
Subject(s) - medicine , bone marrow , cyclophosphamide , lymphoma , transplantation , gastroenterology , surgery , total body irradiation , chemotherapy
We present the clinical results of allogeneic bone marrow transplantation (BMT) with T‐cell‐depleted grafts from HLA‐matched sibling donors in patients with poor‐risk relapsed low‐grade non‐Hodgkin's lymphoma (NHL). Poor risk was defined as relapse within 12 months after or progression during prior treatment. The conditioning regimen consisted of cyclophosphamide and total‐body irradiation with or without additional idarubicin. Donor marrow was depleted of T lymphocytes using counterflow centrifugation. Post‐BMT prophylaxis of graft‐versus‐host disease (GvHD) consisted of cyclosporine A. 15 patients with a median age of 47 years (range 30–57) were transplanted. All patients engrafted. After a median follow‐up of 36 months (range 9–78), 10 patients were alive and in complete remission (CR). Two of them had relapsed after BMT but re‐entered CR following infusions of leucocytes from the original bone marrow donor. Five patients died; causes of death were cardiomyopathy ( n = 1), chronic GvHD ( n = 1) and infection during chronic GvHD ( n = 3). We conclude that allogeneic T‐cell‐depleted bone marrow transplantation is an efficacious treatment for patients with poor‐risk relapsed low‐grade NHL. Infusions of donor leucocytes reinduced CR in the two patients with relapse after BMT.